Raykov Rosty 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Raykov Rosty
Director
Transactions
- Award
Common shares
2025-12-31+5,208→ 82,734 total - Exercise/Conversion
Common shares
2026-01-02$2.45/sh+15,598$38,215→ 98,332 total - Sale
Common shares
2026-01-02$7.60/sh−10,312$78,371→ 88,020 total - Exercise/Conversion
Stock Options
2026-01-02$2.45/sh−15,598$38,215→ 1,618,586 totalExercise: $2.45From: 2016-07-05Exp: 2026-07-05→ Options (15,598 underlying)
Footnotes (4)
- [F1]Represents shares released from restriction from shares awarded 3/31/2023 and 5/16/2024.
- [F2]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on September 19, 2025.
- [F3]Shares sold to satisfy tax obligation on option exercise.
- [F4]Represents options exercised pursuant to a 10b5-1 plan adopted on September 19, 2025.